Semaglutide is a GLP-RA currently authorized for treatment of type 2 diabetes patients with insufficient glycaemic control and long-term weight management. Current dosage forms are administered either by once-weekly subcutaneous injection or by daily oral pill. AdoGel® is a hydrogel platform consisting of cross-linked degradable polymers injectable with 25G needle that allows sustained release of soluble peptides over 1 to 3 months duration. The challenge is to tailor the hydrogel to entrap the peptides to limit initial burst and, at the same time, to allow smooth release by controlled degradation of the hydrogel without generating toxic molecules. An AdoGel-semaglutide formulation was tested in rats (N=6) following a subcutaneous injection. The pharmacokinetics analysis showed limited burst and a regular release over a one-month period. The product is well tolerated with no inflammatory reaction during the one-month period. The results showed that a regular release of semaglutide over one month is achievable and could be a real benefit for patient compliance by limiting the injection frequencies, reduction of side effects and improved efficacy.
A. Marechal: Employee; ADOCIA. Stock/Shareholder; ADOCIA. R. Besnard: Employee; ADOCIA. Stock/Shareholder; ADOCIA. S. Hakim: Employee; ADOCIA. Stock/Shareholder; ADOCIA. U. Naessens: Employee; ADOCIA. Stock/Shareholder; ADOCIA. O. Soula: Board Member; ADOCIA. Stock/Shareholder; ADOCIA. M. Gaudier: Employee; ADOCIA. Stock/Shareholder; ADOCIA. E. Dauty: Stock/Shareholder; ADOCIA. Employee; ADOCIA. C. Megret: Employee; ADOCIA. Stock/Shareholder; ADOCIA. Consultant; Avadel. Stock/Shareholder; Avadel, Sanofi.
